Frontotemporal dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study.
|
31701893 |
2019 |
Frontotemporal dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Neurofilament light chain as a blood biomarker to differentiate psychiatric disorders from behavioural variant frontotemporal dementia.
|
30953863 |
2019 |
Frontotemporal dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Levels of CSF NFL are associated with cognitive impairments in patients with Alzheimer disease and frontotemporal dementia.
|
30508027 |
2019 |
Frontotemporal dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The single biomarkers or biomarker combinations generating the best area under the receiver operating characteristics (AUROCs) were the following: the combination [amyloid β peptide + phosphorylated tau + neurofilament light chain] for distinguishing between ADD patients and HC (AUROC = 0.86), t-tau for distinguishing between ADD and FTD patients (AUROC = 0.82), and t-tau for distinguishing between FTD patients and HC (AUROC = 0.78).
|
29328927 |
2018 |
Frontotemporal dementia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Cerebrospinal fluid NFL levels were quantified in nonprimarily neurodegenerative neurological and psychiatric diseases (n = 122), mild cognitive impairment (n = 48), Alzheimer's disease (n = 108), dementia with Lewy bodies/Parkinson's disease dementia (n = 53), vascular dementia (n = 46), frontotemporal dementia (n = 41), sporadic Creutzfeldt-Jakob disease (sCJD, n = 132), and genetic prion diseases (n = 182).
|
29391125 |
2018 |
Frontotemporal dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
To examine the clinical value of neurofilament light chain (NfL) and the phospho-tau/total tau ratio (p/t-tau) across the entire frontotemporal dementia (FTD) spectrum in a large, well-defined cohort.
|
29514947 |
2018 |
Frontotemporal dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We analyzed 3 CSF biomarkers: the soluble β-fragment of amyloid precursor protein (sAPPβ), YKL-40, and neurofilament light (NfL) in FTD (n = 86), ALS (n = 38), and a group of age-matched cognitively normal controls (n = 49).
|
30291183 |
2018 |
Frontotemporal dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
To evaluate poly(GP), a dipeptide repeat protein, and neurofilament light chain (NfL) as biomarkers in presymptomatic <i>C9orf72</i> repeat expansion carriers and patients with <i>C9orf72-</i>associated frontotemporal dementia.
|
29761121 |
2018 |
Frontotemporal dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cerebrospinal fluid (CSF) neurofilament light chain protein (NfL) and Alzheimer's disease (AD) core biomarker levels have been evaluated in cohorts of patients with frontotemporal dementia spectrum (FTD), but the distribution of values across the different clinical syndromes and underlying proteinopathies, and the relative diagnostic accuracy appear discordant among studies.
|
30320576 |
2018 |
Frontotemporal dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
In sum, CSF-Neurofilament light chain and CSF-Progranulin seem to be promising biomarkers for FTD, the latter predominantly for assumed TDP43-mediated FTD.
|
30013506 |
2018 |
Frontotemporal dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Higher concentrations of CSF NFL were associated with shorter survival in both MND and FTD.
|
28631955 |
2017 |
Frontotemporal dementia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The levels of CSF NF-L detected in p25 mice are about 4-fold higher than the CSF levels detected in patients with chronic neurodegenerative diseases, such as symptomatic FTD (bvFTD).
|
28392472 |
2017 |
Frontotemporal dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We assessed the diagnostic accuracy of cerebrospinal fluid (CSF) neurofilament light chain (NFL) protein in the classification of patients with Alzheimer's disease (AD) and cognitively healthy control individuals (HCs) and patients with frontotemporal dementia (FTD) as comparisons.
|
28527630 |
2017 |
Frontotemporal dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia.
|
27581216 |
2016 |